Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Carcinoma, Merkel Cell × cemiplimab × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 1 Motor Activity 1 Melanoma 1 Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 1 cemiplimab 1 avelumab 1 Nivolumab 1 Ipilimumab 1 Immune Checkpoint Inhibitors 1 Exercise 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡